Results 11 to 20 of about 22,974 (229)
Health disparities in chronic liver disease
Hepatology, EarlyView., 2022 Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian +3 more
wiley +1 more source
Naltrexone Implant for Opioid Use Disorder
Neurology International, 2021 The continued rise in the availability of illicit opioids and opioid-related deaths in the United States has left physicians, researchers, and lawmakers desperate for solutions to this ongoing epidemic.
Amber N. Edinoff +10 more
doaj +1 more source
Low-dose and high-dose naltrexone in opioid dependence syndrome: a three months outcome study
Open Journal of Psychiatry and Allied Sciences, 2019 Background: Naltrexone is effective in the treatment of opioid dependence syndrome (ODS) as it prevents relapse. To effectively design a cost-effective treatment modality for ODS using naltrexone as low as 25 mg is something which is worth exploring. Aim:
Ajeet Sidana +2 more
doaj +1 more source
Opioid-positive urine drug screen during treatment with oral naltrexone and the clinical implications [PDF]
Mental Health ClinicianIntroduction Naltrexone is an opioid antagonist that is FDA approved to treat alcohol dependence and opioid dependence. It is available as an oral tablet and an extended-release injectable suspension.
Elena R. Beauregard, PharmD, BCPS +1 more
doaj +1 more source
Drugs in R&D, 2010 In March 2010, Orexigen(R) Therapeutics submitted a new drug application (NDA) for approval of naltrexone sustained release (SR)/bupropion SR (Contrave(R)) for the treatment of obesity in the US. The tablet contains naltrexone SR 32 mg and bupropion SR 360 mg.
openaire +2 more sources
Naltrexone Protects Against Lipopolysaccharide/D-Galactosamine–Induced Hepatitis in Mice
Journal of Pharmacological Sciences, 2008 Naltrexone, an opioid receptor antagonist, has been claimed to have anti-inflammatory and immunomodulatory effects both in vitro and in vivo.
Chien-Chuan Wang +5 more
doaj +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2022 Sarah Dahlberg,1 Ellen T Chang,1 Sheila R Weiss,1 Pamela Dopart,1 Errol Gould,2 Mary E Ritchey3 1Exponent, Inc, Menlo Park, CA, 94025, USA; 2Currax Pharmaceuticals LLC., Brentwood, TN, 37027, USA; 3Med Tech Epi, LLC., Philadelphia, PA, 19147 ...
Dahlberg S +5 more
doaj
The effects of Naltrexone among alcohol non-abstainers: results from the COMBINE Study
Frontiers in Psychiatry, 2010 These analyses of the COMBINE Study examined the effects of naltrexone among non-abstainers. Given that one of the most well-established mechanisms of action of naltrexone involves blunting of alcohol reward, it is hypothesized that naltrexone should be ...
Lara Ray +2 more
doaj +1 more source
Exploring genetic predictors of naltrexone treatment response in opioid use disorder
Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2019 Purpose: The present study was aimed to evaluate the effect of the opioid receptors genes and dopamine system genes polymorphisms on the treatment outcomes of opioid dependence with implantable and oral naltrexone in randomized double blinded double ...
Е. A. Blokhina . +6 more
doaj +1 more source